Science Explorer Back to mapMap
Discussion
Company · Cambridge · United States

Alnylam Pharmaceuticals (United States)

In research, Alnylam Pharmaceuticals (United States) stands highest in Life Sciences (#1,269 of 11,023 worldwide), Biochemistry, Genetics and Molecular Biology (#811 of 5,801 worldwide) and Molecular Biology (#624 of 3,729 worldwide), over all time. Relative to its size it is most specialised in Molecular Biology and Biochemistry, Genetics and Molecular Biology (Molecular Biology is 12.2× its share of world research).

World rank, 2022-now
#9,182
of 22,385 · #5,239 all time
Rank in United States
#1,242
of 3,332
Research works
344
▼ 7% vs 2018-21
Citations
25k
73.5 per fractional work
Top-10% rate
15.5%
all institutions 10.0%
vs its own fields
1.01×
1.00× is exactly expected
Open access
50%
world 40%
International
31%
world 18%

What is Alnylam Pharmaceuticals (United States) known for in research?

The fields where it stands highest, over all time, ranked among every institution above the floor in each field.

FieldWorld rankWhere that sitsTop-10% rateWorks
Life SciencesDomain #1,269 of 11,023 24.7%210
Biochemistry, Genetics and Molecular BiologyField #811 of 5,801 24.9%190
Molecular BiologySubfield #624 of 3,729 23.6%152

Each strip is that field's whole ranked pool, with the notch where Alnylam Pharmaceuticals (United States) sits in it, in the colour of the band that rank falls in. The track under the rate is the rate itself: it carries no average mark, because the average differs by field (from about 6% in Dentistry to 21% in Economics).

Which fields of science does Alnylam Pharmaceuticals (United States) work in?

In 2022-now, 54% of research at Alnylam Pharmaceuticals (United States) is in Life Sciences, 39% in Health Sciences. Its largest fields are Biochemistry, Genetics and Molecular Biology (47%), Medicine (38%), Immunology and Microbiology (3%). It does 3.5× the world's share of Life Sciences.

Life Sciences: 58 fractional works · 53.6% of its workBiochemistry, Genetics and Molecular Biology: 51 fractional works · 47.4% of its workMolecular Biology: 40 fractional works · 36.7% of its workGenetics: 4 fractional works · 3.5% of its workCancer Research: 3 fractional works · 2.7% of its workCell Biology: 2 fractional works · 2.1% of its workBiophysics: 1 fractional works · 1.1% of its workClinical Biochemistry: 1 fractional works · 0.7% of its workPhysiology: 0 fractional works · 0.2% of its workSmaller subfields together: 0 fractional works · 0.4% of its workImmunology and Microbiology: 3 fractional works · 2.8% of its workImmunology: 3 fractional works · 2.5% of its workSmaller subfields together: 0 fractional works · 0.3% of its workNeuroscience: 2 fractional works · 1.4% of its workCognitive Neuroscience: 1 fractional works · 0.5% of its workCellular and Molecular Neuroscience: 0 fractional works · 0.4% of its workDevelopmental Neuroscience: 0 fractional works · 0.3% of its workSmaller subfields together: 0 fractional works · 0.1% of its workAgricultural and Biological Sciences: 1 fractional works · 1.1% of its workFood Science: 0 fractional works · 0.5% of its workSmaller subfields together: 1 fractional works · 0.6% of its workPharmacology, Toxicology and Pharmaceutics: 1 fractional works · 1.0% of its workPharmacology: 1 fractional works · 0.9% of its workSmaller subfields together: 0 fractional works · 0.1% of its workHealth Sciences: 42 fractional works · 39.4% of its workMedicine: 41 fractional works · 38.4% of its workCardiology and Cardiovascular Medicine: 5 fractional works · 4.7% of its workNephrology: 4 fractional works · 3.3% of its workPulmonary and Respiratory Medicine: 3 fractional works · 3.2% of its workPhysiology: 3 fractional works · 3.0% of its workEndocrinology, Diabetes and Metabolism: 3 fractional works · 2.9% of its workRheumatology: 3 fractional works · 2.3% of its workPediatrics, Perinatology and Child Health: 2 fractional works · 2.1% of its workEpidemiology: 2 fractional works · 2.0% of its workPathology and Forensic Medicine: 2 fractional works · 2.0% of its workGenetics: 2 fractional works · 1.8% of its workNeurology: 2 fractional works · 1.7% of its workPsychiatry and Mental health: 2 fractional works · 1.5% of its workOncology: 1 fractional works · 1.2% of its workHepatology: 1 fractional works · 1.0% of its workPharmacology: 1 fractional works · 0.8% of its workInfectious Diseases: 1 fractional works · 0.8% of its workRadiology, Nuclear Medicine and Imaging: 1 fractional works · 0.8% of its workSurgery: 1 fractional works · 0.5% of its workHematology: 1 fractional works · 0.5% of its workObstetrics and Gynecology: 0 fractional works · 0.5% of its workPublic Health, Environmental and Occupational Health: 0 fractional works · 0.4% of its workOphthalmology: 0 fractional works · 0.3% of its workAnatomy: 0 fractional works · 0.3% of its workSmaller subfields together: 1 fractional works · 0.6% of its workNursing: 1 fractional works · 0.8% of its workNutrition and Dietetics: 1 fractional works · 0.8% of its workVeterinary: 0 fractional works · 0.2% of its workHealth Professions: 0 fractional works · 0.1% of its workPhysical Sciences: 5 fractional works · 4.7% of its workEngineering: 2 fractional works · 1.7% of its workBiomedical Engineering: 1 fractional works · 1.0% of its workControl and Systems Engineering: 0 fractional works · 0.3% of its workSmaller subfields together: 0 fractional works · 0.3% of its workChemistry: 1 fractional works · 1.2% of its workOrganic Chemistry: 1 fractional works · 0.9% of its workAnalytical Chemistry: 0 fractional works · 0.3% of its workComputer Science: 1 fractional works · 0.6% of its workComputational Theory and Mathematics: 1 fractional works · 0.5% of its workSmaller subfields together: 0 fractional works · 0.1% of its workMathematics: 0 fractional works · 0.4% of its workStatistics and Probability: 0 fractional works · 0.4% of its workPhysics and Astronomy: 0 fractional works · 0.3% of its workMaterials Science: 0 fractional works · 0.2% of its workEarth and Planetary Sciences: 0 fractional works · 0.2% of its workEnvironmental Science: 0 fractional works · 0.2% of its workSocial Sciences: 3 fractional works · 2.4% of its workDecision Sciences: 1 fractional works · 0.8% of its workManagement Science and Operations Research: 0 fractional works · 0.4% of its workStatistics, Probability and Uncertainty: 0 fractional works · 0.3% of its workSmaller subfields together: 0 fractional works · 0.1% of its workEconomics, Econometrics and Finance: 1 fractional works · 0.5% of its workEconomics and Econometrics: 1 fractional works · 0.5% of its workPsychology: 0 fractional works · 0.5% of its workClinical Psychology: 0 fractional works · 0.4% of its workSmaller subfields together: 0 fractional works · 0.1% of its workSocial Sciences: 0 fractional works · 0.3% of its workCultural Studies: 0 fractional works · 0.2% of its workSmaller subfields together: 0 fractional works · 0.1% of its workArts and Humanities: 0 fractional works · 0.3% of its workLanguage and Linguistics: 0 fractional works · 0.2% of its workSmaller subfields together: 0 fractional works · 0.1% of its workBusiness, Management and Accounting: 0 fractional works · 0.0% of its workALL ITS WORKAlnylamPharmaceuticals…108fractional works, 2022-now
Life Sciences54%Physical Sciences5%Health Sciences39%Social Sciences2%

Each ring splits the one inside it: the four domains of science, their fields, their subfields. Size is fractional works in 2022-now. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.

Its 4 domains and 23 fields, with their numbers
    1. Biochemistry, Genetics and Molecular Biology5147.4%
    2. Immunology and Microbiology32.8%
    3. Neuroscience21.4%
    4. Agricultural and Biological Sciences11.1%
    5. Pharmacology, Toxicology and Pharmaceutics11.0%
    1. Medicine4138.4%
    2. Nursing10.8%
    3. Veterinary00.2%
    4. Health Professions00.1%
    1. Engineering21.7%
    2. Chemistry11.2%
    3. Computer Science10.6%
    4. Mathematics00.4%
    5. Physics and Astronomy00.3%
    6. Materials Science00.2%
    7. Earth and Planetary Sciences00.2%
    8. Environmental Science00.2%
    1. Decision Sciences10.8%
    2. Economics, Econometrics and Finance10.5%
    3. Psychology00.5%
    4. Social Sciences00.3%
    5. Arts and Humanities00.3%
    6. Business, Management and Accounting00.0%
All of science, and how each field's share has moved since 1950: the Science domain explorer

What does Alnylam Pharmaceuticals (United States) specialise in?

Where its research is concentrated relative to its size: Molecular Biology takes 12.2× the share of its output that it takes of world research.

  1. Molecular BiologySubfield · 39.7 works12×
  2. Biochemistry, Genetics and Molecular BiologyField · 51.2 works8.9×
← less than its size predicts1×more →

Location quotient, a volume reading rather than an impact one. It surfaces small, lopsided specialities.

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Agricultural and Biological Sciences: 0.22× its world share, 1 worksAgricultural and Bio…Biochemistry, Genetics and Molecular Biology: 8.90× its world share, 51 worksBiochemistry, Geneti…Immunology and Microbiology: 2.76× its world share, 3 worksImmunology and Micro…Neuroscience: 0.86× its world share, 2 worksNeurosciencePharmacology, Toxicology and Pharmaceutics: 2.75× its world share, 1 worksPharmacology, Toxico…Chemistry: 0.74× its world share, 1 worksChemistryComputer Science: 0.07× its world share, 1 worksComputer ScienceEarth and Planetary Sciences: 0.10× its world share, 0 worksEarth and Planetary …Engineering: 0.11× its world share, 2 worksEngineeringEnvironmental Science: 0.03× its world share, 0 worksEnvironmental ScienceMaterials Science: 0.06× its world share, 0 worksMaterials ScienceMathematics: 0.37× its world share, 0 worksMathematicsPhysics and Astronomy: 0.14× its world share, 0 worksPhysics and AstronomyHealth Professions: 0.02× its world share, 0 worksHealth ProfessionsMedicine: 2.00× its world share, 42 worksMedicineNursing: 1.54× its world share, 1 worksNursingVeterinary: 1.18× its world share, 0 worksVeterinaryArts and Humanities: 0.10× its world share, 0 worksArts and HumanitiesBusiness, Management and Accounting: 0.01× its world share, 0 worksBusiness, Management…Decision Sciences: 0.80× its world share, 1 worksDecision SciencesEconomics, Econometrics and Finance: 0.24× its world share, 0 worksEconomics, Econometr…Psychology: 0.15× its world share, 0 worksPsychologySocial Sciences: 0.02× its world share, 0 worksSocial Sciences1×world share
more than its size predictsabout as predictedless

Rings at 0.5×, 1× and 2×. Widest outward: Biochemistry, Genetics and Molecular Biology, 8.9×. Every wedge is a field page.

All 23 fields, with their numbers
  1. Biochemistry, Genetics and Molecular Biology8.90×51 works
  2. Immunology and Microbiology2.76×3 works
  3. Pharmacology, Toxicology and Pharmaceutics2.75×1 works
  4. Medicine2.00×42 works
  5. Nursing1.54×1 works
  6. Veterinary1.18×0 works
  7. Neuroscience0.86×2 works
  8. Decision Sciences0.80×1 works
  9. Chemistry0.74×1 works
  10. Mathematics0.37×0 works
  11. Economics, Econometrics and Finance0.24×0 works
  12. Agricultural and Biological Sciences0.22×1 works
  13. Psychology0.15×0 works
  14. Physics and Astronomy0.14×0 works
  15. Engineering0.11×2 works
  16. Earth and Planetary Sciences0.10×0 works
  17. Arts and Humanities0.10×0 works
  18. Computer Science0.07×1 works
  19. Materials Science0.06×0 works
  20. Environmental Science0.03×0 works
  21. Health Professions0.02×0 works
  22. Social Sciences0.02×0 works
  23. Business, Management and Accounting0.01×0 works

Who are the top researchers at Alnylam Pharmaceuticals (United States)?

Ranked on the quality score, Akin Akinc, Kallanthottathil G. Rajeev and Kevin J. Fitzgerald lead among researchers whose main affiliation is Alnylam Pharmaceuticals (United States).

  1. 1 Akin Akinc United States · #36,432 worldwide 25k citations · 79 works
  2. 2 Kallanthottathil G. Rajeev United States · #37,698 worldwide 22k citations · 91 works
  3. 3 Kevin J. Fitzgerald United States · #41,280 worldwide 23k citations · 157 works
  4. 4 Stuart Milstein United States · #57,895 worldwide 13k citations · 69 works
  5. 5 Akshay K. Vaishnaw United States · #62,226 worldwide 14k citations · 97 works
  6. 6 Klaus Charissé United States · #82,843 worldwide 12k citations · 105 works
  7. 7 Martin A. Maier United States · #89,441 worldwide 18k citations · 160 works
  8. 8 Muthiah A. Manoharan United States · #101,175 worldwide 41k citations · 346 works
  9. 9 Lucas D. Ward United States · #110,201 worldwide 52k citations · 82 works
  10. 10 Marianne T. Sweetser United States · #114,213 worldwide 13k citations · 115 works
All ranked researchers at Alnylam Pharmaceuticals (United States)

What are the most cited papers from Alnylam Pharmaceuticals (United States)?

The most cited paper from Alnylam Pharmaceuticals (United States) is "Silencing of microRNAs in vivo with ‘antagomirs’" (Jan Krützfeldt, Nikolaus Rajewsky, Ravi S Braich et al., 2005), with 3,987 citations. Next come "Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis" (3,046) and "MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts" (2,368).

Most cited papers
#PaperReleasedCitations
1 Silencing of microRNAs in vivo with ‘antagomirs’ Jan Krützfeldt, Nikolaus Rajewsky, Ravi S Braich et al. · Nature 30 Oct 2005 3,987
2 Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis David H Adams et al. · New England Journal of Medicine Open access 4 Jul 2018 3,046
3 MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts Thomas Thum et al. · Nature 30 Nov 2008 2,368
4 Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs Jürgen Soutschek et al. · Nature Nov 2004 2,191
5 Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters Markus Feuerer, Laura Herrero, Daniela Cipolletta et al. · Nature Medicine Open access 26 Jul 2009 2,160
All 60 most cited papers, with filters and sorting

Which keywords describe research at Alnylam Pharmaceuticals (United States)?

By fractional works in 2022-now, weighted toward what it does more of than the world: Treatment, Diagnosis, Prognosis, Gene Therapy, Cardiovascular Magnetic Resonance, Cardiac Amyloidosis, Transthyretin and RNA Interference.

▲ more of its work than of the world's◆ about the world's share▼ less than the world's

Size is fractional works in 2022-now in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.

All 40 words, with their numbers
  1. Treatment12▲ 9.4×12 topics
  2. Diagnosis11▲ 11×10 topics
  3. Gene Therapy9▲ 44×3 topics
  4. Prognosis9▲ 26×5 topics
  5. Cardiovascular Magnetic Resonance9▲ 155×2 topics
  6. Cardiac Amyloidosis9▲ 377×1 topic
  7. Transthyretin9▲ 377×1 topic
  8. Inflammation9▲ 3.8×31 topics
  9. RNA Interference8▲ 95×1 topic
  10. siRNA Delivery8▲ 137×1 topic
  11. Oxidative Stress8▲ 4.5×18 topics
  12. Nanoparticles6▲ 4.0×7 topics
  13. Vitamin B126▲ 147×2 topics
  14. Cardiovascular Disease5▲ 4.4×14 topics
  15. Genetic Mutations5▲ 11×8 topics
  16. Metabolic Syndrome5▲ 5.8×10 topics
  17. Biosensors5▲ 9.4×2 topics
  18. DNA nanotechnology5▲ 40×1 topic
  19. Hypertension5▲ 16×9 topics
  20. Self-Assembly5▲ 14×1 topic
  21. Liver Transplantation5▲ 36×4 topics
  22. Cancer4▲ 3.0×20 topics
  23. Genomic Analysis4▲ 15×3 topics
  24. Heme Biosynthesis4▲ 544×1 topic
  25. Porphyrias4▲ 544×1 topic
  26. Management4▲ 4.5×4 topics
  27. Risk Factors4▲ 3.2×9 topics
  28. Chronic Kidney Disease4▲ 13×6 topics
  29. Biomarkers3▲ 4.2×9 topics
  30. Therapeutic Targets3▲ 19×3 topics
  31. Nucleic Acids3▲ 97×2 topics
  32. Antisense Oligonucleotides3▲ 66×2 topics
  33. DNA Structure3▲ 137×1 topic
  34. G-Quadruplexes3▲ 137×1 topic
  35. Apoptosis3▲ 8.4×7 topics
  36. Parathyroid Hormone3▲ 27×3 topics
  37. Cardiovascular Events3▲ 21×3 topics
  38. FGF233▲ 70×1 topic
  39. Neuroprotection3▲ 7.0×5 topics
  40. phosphate3▲ 70×1 topic

Which research topics does Alnylam Pharmaceuticals (United States) publish most on?

By volume in 2022-now: Amyloidosis: Diagnosis, Treatment, Outcomes, RNA Interference and Gene Delivery, Advanced biosensing and bioanalysis techniques and Porphyrin Metabolism and Disorders.

  1. 1 Amyloidosis: Diagnosis, Treatment, Outcomes Molecular Biology 9 works
  2. 2 RNA Interference and Gene Delivery Molecular Biology 8 works
  3. 3 Advanced biosensing and bioanalysis techniques Molecular Biology 5 works
  4. 4 Porphyrin Metabolism and Disorders Molecular Biology 4 works
  5. 5 DNA and Nucleic Acid Chemistry Molecular Biology 3 works
  6. 6 Parathyroid Disorders and Treatments Nephrology 3 works
  7. 7 Kidney Stones and Urolithiasis Treatments Pulmonary and Respiratory Medicine 2 works
  8. 8 Heme Oxygenase-1 and Carbon Monoxide Molecular Biology 2 works
  9. 9 Alzheimer's disease research and treatments Physiology 2 works
  10. 10 MicroRNA in disease regulation Cancer Research 2 works

How open and international is its research?

Against the world's own shares: the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available50.4%not open49.6%

World: 40% of research is openly available.

with international co-authors31.0%domestic only69.0%

World: 18% is written across borders.

How has Alnylam Pharmaceuticals (United States)'s research output changed?

Output in 2022-2025 was 7% lower than in 2018-2021.

still counting200020102020
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is Alnylam Pharmaceuticals (United States) as a percentage of every work published that year, 0.00044% in 2024.

still counting0.00025%0.00050%0.00075%Alnylam Pharmaceuticals (United States)0.00043% in 2025200020102020

Fractional works of Alnylam Pharmaceuticals (United States) over all fractional works that year. How the balance of science has shifted.

How much of it reaches the world top 10%

Year by year, against all institutions in the same year.

still counting10%20%30%Alnylam Pharmaceuticals (United States)16.9% in 2025all institutions10.0% in 20252020

Of each year's output, the share that reached the world's 10% most cited for its field and year. Peak 27.6% in 2012.

Other research institutions in Cambridge

All research institutions in Cambridge

Share Alnylam Pharmaceuticals (United States)'s ranking

Alnylam Pharmaceuticals (United States) on Science Explorer

A card with Alnylam Pharmaceuticals (United States)'s standing and the fields it leads in, for a post or a slide. A link to this page previews as the same card.

Download the card

1200 × 630 PNG, sized for social posts, drawn from the latest snapshot.

Badges for a website1Each links back here and updates with every snapshot

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.

Discussion

Ask a question or share a note about Alnylam Pharmaceuticals (United States). Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.